Toxicological studies as a critical factor for the pharmaceutical development and approval process.

 Toxicological studies form the critical part of the drug development process as it involves identification of candidates and their synthesis followed by characterization, validation and optimization. This is further followed by screening and assays for efficiency and therapeutic efficacy. This process development involves preclinical and clinical studies.

TOXICOLOGY STUDIES FOR PHARMACEUTICAL DEVELOPMENT AND APPROVAL: 

It is observed that once a compound shows some therapeutic efficacy it will also exhibit some significance with respect to the investigations done on the basis of drug development process earlier to clinical trials. Toxicological studies are important to understand the order of the development process conducted at various stages to manufacture a medicine that is efficacious, safe and has approved the regulatory requirements and specifications. It is necessary to timely and periodically validate the method development process using the rightful research tools for the clinical use of the biological targets since the process is very long, complex and expensive. It is a challenging task to bring the medicine into the market after the discovery, development and manufacture.

 The primary objective of toxicology studies is to assess the potential adverse effects and risks associated with these compounds. These studies are typically conducted using animal models, such as rodents or non-human primates, to provide insights into the effects of the drug on living organisms. The toxicology studies must be followed with the guidelines for safety evaluation as well as validation of the toxicological profile of the compound. The toxicology profile of the drug compound validation involves various pharmacological studies including safety, genetic toxicology, chronic toxicology studies, acute and sub-chronic toxicology, ADME studies, reproductive and developmental toxicology and evaluation of carcinogenic potential.

The non- clinical studies of the process development have animal models and related studies followed by good laboratory practice (GLP) regulations. Whereas in the pre-clinical developmental process, a drug candidate needs to clear several tests based on bioavailability, pharmacokinetics and ADME studies along with the preliminary studies for the evaluation of genotoxicity, mutagenicity and general toxicological studies. These studies are critical for the drug development provided they are following GLP standards and approval guidelines and regulations from the concerned regulatory bodies. Additionally these studies are conducted thoroughly before IND application and mandatory for the safety concerns.

The preclinical toxicology research is conducted and designed specifically for the comprehensive analysis of the drug safety margins to decide upon the channel of the treatment that can be done for a particular disease. This enables the researchers to understand and gain insights into the in-depth knowledge of the toxicity mechanisms, translatability functions, functional analysis, safety requirements, and mitigation of side effects and development of safety biomarkers.

The main objective of the investigational toxicology is about the clinical safety that gives the predictive knowledge about the chemical and physical properties of the drug candidate. The computational approach enables one to understand the risk factor involved thus managing the drug design and candidate selection in an optimized way to bring the clinical trials successfully. The predictive measures taken can be used to study the physiological model systems and all aspects of the toxicity endpoints.